Investigating how mitochondrial signals affect Alzheimer's disease progression
Mitochondrial complex III-derived ROS in astrocytic signaling and Alzheimer's disease-related pathogenesis
This study is looking at how certain molecules made by our cells might play a role in Alzheimer's disease, and it's working on creating new treatments that could help reduce these molecules to improve brain health for people with Alzheimer's and related conditions.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10915455 on NIH RePORTER |
What this research studies
This research explores the role of reactive oxygen species (ROS) produced by mitochondria in the development of Alzheimer's disease and related dementias. By focusing on mitochondrial complex III, the study aims to understand how these ROS influence cell signaling and contribute to neuroinflammation and other pathological processes in Alzheimer's. The researchers are developing small molecules that selectively suppress ROS production from complex III without affecting other mitochondrial functions. This targeted approach could lead to new therapeutic strategies for managing Alzheimer's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related dementias.
Not a fit: Patients with non-neurological conditions or those without any form of dementia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to novel treatments that slow down or alter the progression of Alzheimer's disease.
How similar studies have performed: Previous research has shown promising results in targeting mitochondrial ROS in other neurological disorders, suggesting potential for success in this novel approach.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Barnett, Daniel Martin — Weill Medical Coll of Cornell Univ
- Study coordinator: Barnett, Daniel Martin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.